NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02987543,Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study),https://clinicaltrials.gov/study/NCT02987543,,COMPLETED,The purpose of this study is to evaluate the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations.,YES,Metastatic Castration-resistant Prostate Cancer,DRUG: olaparib|DRUG: enzalutamide|DRUG: abiraterone acetate|DRUG: abiraterone acetate|DRUG: enzalutamide,"Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A Only, The time from randomisation until the date of objective radiological disease progression (determined by RECIST 1.1 (soft tissue) and Prostate Cancer Working Group 3 (PCWG-3) (bone)) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from randomised therapy or received another anti-cancer therapy prior to progression. Progression is defined using (i) Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for soft tissue, as a \>=20% increase in the sum of diameters of target lesions and an absolute increase of \>=5mm taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters; (ii) Prostate Cancer Working Group 3 (PGWG-3) for bone as \>= 2 new bone lesions on the 1st week 8 scan compared to baseline. The confirmatory scan, \>=6 weeks later, must show \>=2 more new bone lesions (for a total of \>=4 new bone lesions since baseline)., Tumor assessments every 8 weeks from randomisation until radiographic progression assessed by BICR (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).","Confirmed Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) - Cohort A Only, ORR is the percentage of patients with at least one visit response of Complete response (CR) or Partial response (PR), in their soft tissue disease assessed by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), in the absence of progression on bone scan assessed by Prostate Cancer Working Group 3 (PCWG3)). Per RECIST v1.1, CR=Disappearance of all target lesions; PR = \>=30% decrease in the sum of diameters of target lesions; For each treatment group, ORR is the number of patients with a CR and PR., Tumor assessments every 8 weeks from randomisation until radiographic progression assessed by BICR (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).|Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A+B, The time from randomisation until the date of objective radiological disease progression (by RECIST 1.1 and Prostate Cancer Working Group 3 (PGWG-3)) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from randomised therapy or received another anti-cancer therapy prior to progression., Tumor assessments every 8 weeks from randomisation until radiographic progression assessed by BICR (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).|Time to Pain Progression - Cohort A Only, Time from randomisation to time point at which worsening in pain is observed (ie date of pain progression - date of randomisation + 1). Based on average Brief Pain Inventory - short form (BPI-SF) worst pain \[Item 3\] and Analgesic Quantification Algorithm \[AQA\] score., Every 4 weeks from randomisation (for 7 consecutive days) throughout the study (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).|Overall Survival (OS) - Cohort A Only, Number of Participants with Overall Survival (OS) - Cohort A only., Approximately 35 months after the first patient was randomised.",,AstraZeneca,"Merck Sharp & Dohme LLC|Foundation Medicine|Myriad Genetics, Inc.",MALE,"ADULT, OLDER_ADULT",PHASE3,387,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,D081DC00007|2016-000300-28,2017-02-06,2019-06-04,2023-02-15,2016-12-09,2020-10-12,2023-10-06,"Research Site, Anchorage, Alaska, 99503, United States|Research Site, Tucson, Arizona, 85704, United States|Research Site, Tucson, Arizona, 85741, United States|Research Site, Duarte, California, 91010, United States|Research Site, San Diego, California, 92161, United States|Research Site, Santa Barbara, California, 93105, United States|Research Site, Washington, District of Columbia, 20007, United States|Research Site, Tampa, Florida, 33612, United States|Research Site, Atlanta, Georgia, 30318, United States|Research Site, Chicago, Illinois, 60611, United States|Research Site, Jeffersonville, Indiana, 47130, United States|Research Site, New Orleans, Louisiana, 70112, United States|Research Site, Baltimore, Maryland, 21287, United States|Research Site, Towson, Maryland, 21204, United States|Research Site, Omaha, Nebraska, 68130, United States|Research Site, Las Vegas, Nevada, 89135, United States|Research Site, Albany, New York, 12208, United States|Research Site, Bronx, New York, 10468, United States|Research Site, Brooklyn, New York, 11201, United States|Research Site, Syracuse, New York, 13210, United States|Research Site, Durham, North Carolina, 27710, United States|Research Site, Salisbury, North Carolina, 28144, United States|Research Site, Columbus, Ohio, 43230, United States|Research Site, Oklahoma City, Oklahoma, 73104, United States|Research Site, Springfield, Oregon, 97477, United States|Research Site, Tualatin, Oregon, 97062, United States|Research Site, Charleston, South Carolina, 29401, United States|Research Site, Myrtle Beach, South Carolina, 29572, United States|Research Site, Germantown, Tennessee, 38138, United States|Research Site, Nashville, Tennessee, 37232, United States|Research Site, San Antonio, Texas, 78229, United States|Research Site, Salt Lake City, Utah, 84112, United States|Research Site, Salt Lake City, Utah, 84148, United States|Research Site, Spokane, Washington, 99202, United States|Research Site, Wheeling, West Virginia, 26003, United States|Research Site, Buenos Aires, 1426, Argentina|Research Site, Buenos Aires, C1118AAT, Argentina|Research Site, Buenos Aires, C1120AAT, Argentina|Research Site, Caba, C1280AEB, Argentina|Research Site, La Rioja, 5300, Argentina|Research Site, Rosario, 2000, Argentina|Research Site, Adelaide, 5000, Australia|Research Site, Box Hill, 3128, Australia|Research Site, Clayton, 3168, Australia|Research Site, Greenslopes, 4120, Australia|Research Site, Herston, 4029, Australia|Research Site, Macquarie University, 2109, Australia|Research Site, Melbourne, 3000, Australia|Research Site, Nedlands, 6009, Australia|Research Site, Randwick, 2031, Australia|Research Site, Waratah, 2298, Australia|Research Site, Graz, 8036, Austria|Research Site, Linz, 4020, Austria|Research Site, Salzburg, 5020, Austria|Research Site, Wien, 1020, Austria|Research Site, Wien, 1090, Austria|Research Site, Barretos, 14784-400, Brazil|Research Site, Belo Horizonte, 30110-022, Brazil|Research Site, Curitiba, 80530-010, Brazil|Research Site, Florianópolis, 88034-000, Brazil|Research Site, Passo Fundo, 99010-080, Brazil|Research Site, Porto Alegre, 90160-093, Brazil|Research Site, Porto Alegre, 90610-000, Brazil|Research Site, Recife, 50040-000, Brazil|Research Site, Ribeirao Preto, 14015-140, Brazil|Research Site, Rio de Janeiro, 22793-080, Brazil|Research Site, Santo Andre, 09060-650, Brazil|Research Site, São José do Rio Preto, 15090-000, Brazil|Research Site, São Paulo, 01321-001, Brazil|Research Site, São Paulo, 03102-002, Brazil|Research Site, Edmonton, Alberta, T6G 1Z2, Canada|Research Site, Kelowna, British Columbia, V1Y 5L3, Canada|Research Site, Vancouver, British Columbia, V5Z 4E6, Canada|Research Site, Hamilton, Ontario, L8V 5C2, Canada|Research Site, Oakville, Ontario, L6H 3P1, Canada|Research Site, Toronto, Ontario, M4N 3M5, Canada|Research Site, Toronto, Ontario, M5G 2M9, Canada|Research Site, Chicoutimi, Quebec, G7H 5H6, Canada|Research Site, Montreal, Quebec, H2X 3E4, Canada|Research Site, Montreal, Quebec, H4A 3J1, Canada|Research Site, Saskatoon, Saskatchewan, S7N 4H4, Canada|Research Site, Quebec, G1J 1Z4, Canada|Research Site, Odense C, 5000, Denmark|Research Site, BESANCON Cedex, 25030, France|Research Site, Bordeaux Cedex, 33000, France|Research Site, Caen, 14000, France|Research Site, Lille, 59020, France|Research Site, Lyon Cedex 08, 69008, France|Research Site, Marseille cedex 09, 13273, France|Research Site, Montpellier, 34298, France|Research Site, Paris, 75014, France|Research Site, Poitiers Cedex, 86021, France|Research Site, Saint Herblain, 44805, France|Research Site, Toulouse Cedex 09, 31100, France|Research Site, Vandoeuvre les Nancy, 54519, France|Research Site, Villejuif, 94805, France|Research Site, Bergisch Gladbach, 51465, Germany|Research Site, Berlin, 13055, Germany|Research Site, Bremen, 28277, Germany|Research Site, Duisburg, 47179, Germany|Research Site, Düsseldorf, 40225, Germany|Research Site, Hamburg, 22399, Germany|Research Site, Heidelberg, 69120, Germany|Research Site, Holzminden, 37603, Germany|Research Site, Jena, 07747, Germany|Research Site, Köln, 50968, Germany|Research Site, Magdeburg, 39120, Germany|Research Site, Nürnberg, 90491, Germany|Research Site, Nürtingen, 72622, Germany|Research Site, Tübingen, 72076, Germany|Research Site, Wuppertal, 42109, Germany|Research Site, Haifa, 31096, Israel|Research Site, Jerusalem, 91120, Israel|Research Site, Kfar Saba, 95847, Israel|Research Site, Petach-Tikva, 4941492, Israel|Research Site, Ramat Gan, 5265601, Israel|Research Site, Zerifin, 70300, Israel|Research Site, Ancona, 60126, Italy|Research Site, Arezzo, 52100, Italy|Research Site, Bari, 70124, Italy|Research Site, Brescia, 25100, Italy|Research Site, Meldola, 47014, Italy|Research Site, Milano, 20133, Italy|Research Site, Milano, 20141, Italy|Research Site, Modena, 41124, Italy|Research Site, Napoli, 80131, Italy|Research Site, Trento, 38100, Italy|Research Site, Bunkyo-ku, 113-8431, Japan|Research Site, Bunkyo-ku, 113-8510, Japan|Research Site, Bunkyo-ku, 113-8603, Japan|Research Site, Fukuoka, 812-8582, Japan|Research Site, Hirosaki-shi, 036-8563, Japan|Research Site, Kanazawa-shi, 920-8641, Japan|Research Site, Kashihara-shi, 634-8522, Japan|Research Site, Kashiwa, 277-8577, Japan|Research Site, Kawagoe-shi, 350-8550, Japan|Research Site, Kita-gun, 761-0793, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kyoto-shi, 606-8507, Japan|Research Site, Maebashi-shi, 371-8811, Japan|Research Site, Matsuyama-shi, 791-0280, Japan|Research Site, Minato-ku, 105-8471, Japan|Research Site, Mitaka-shi, 181-8611, Japan|Research Site, Miyazaki-shi, 889-1692, Japan|Research Site, Nagasaki-shi, 852-8501, Japan|Research Site, Nagoya-shi, 464-8681, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Osaka-shi, 545-8586, Japan|Research Site, Osakasayama-shi, 589-8511, Japan|Research Site, Sagamihara-shi, 252-0375, Japan|Research Site, Sakura-shi, 285-8741, Japan|Research Site, Sapporo-shi, 060-8648, Japan|Research Site, Shinjuku-ku, 160-8582, Japan|Research Site, Suita-shi, 565-0871, Japan|Research Site, Sunto-gun, 411-8777, Japan|Research Site, Yokohama-shi, 232-0024, Japan|Research Site, Busan, 49241, Korea, Republic of|Research Site, Daegu, 41404, Korea, Republic of|Research Site, Goyang-si, 10408, Korea, Republic of|Research Site, Gwangju, 61469, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06273, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 06591, Korea, Republic of|Research Site, Amsterdam, 1066 CX, Netherlands|Research Site, Hilversum, 1213 XZ, Netherlands|Research Site, Leiden, 2333 ZA, Netherlands|Research Site, Nijmegen, 6525 GA, Netherlands|Research Site, Tilburg, 5042 AD, Netherlands|Research Site, Zwolle, 8025 AB, Netherlands|Research Site, Lørenskog, N-1478, Norway|Research Site, Gerona, 17007, Spain|Research Site, Madrid, 08035, Spain|Research Site, Madrid, 28040, Spain|Research Site, Madrid, 28041, Spain|Research Site, Malaga, 29010, Spain|Research Site, Oviedo, 33011, Spain|Research Site, Sevilla, 41009, Spain|Research Site, Göteborg, 413 45, Sweden|Research Site, Solna, 171 64, Sweden|Research Site, Changhua City, 50006, Taiwan|Research Site, Kaohsiung, 807, Taiwan|Research Site, Kaohsiung, 833, Taiwan|Research Site, Taichung, 404, Taiwan|Research Site, Taichung, 40705, Taiwan|Research Site, Tainan, 70403, Taiwan|Research Site, Taipei, 10002, Taiwan|Research Site, Taipei, 112, Taiwan|Research Site, Taoyuan City, 333, Taiwan|Research Site, Adana, 01120, Turkey|Research Site, Ankara, 06230, Turkey|Research Site, Ankara, 06340, Turkey|Research Site, Ankara, 06590, Turkey|Research Site, Edirne, 22030, Turkey|Research Site, Istanbul, 34030, Turkey|Research Site, Istanbul, 34365, Turkey|Research Site, Karsiyaka, 35575, Turkey|Research Site, London, EC1M 6BQ, United Kingdom|Research Site, London, NW1 2PG, United Kingdom|Research Site, Manchester, M20 4BX, United Kingdom|Research Site, Romford, RM7 0BE, United Kingdom|Research Site, Sutton, SM25PT, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/43/NCT02987543/Prot_005.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/43/NCT02987543/SAP_015.pdf"
